Press
-
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
-
Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States
-
Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
-
Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US
-
Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology
-
Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)
-
Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer
-
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network